PEGS_Banner_Engineering-ADCs


From novel payloads to new linkers and conjugation methods, ADC development has reached a new height. Companies are pushing the envelope in ADC design and optimization to achieve the desired properties such as homogeneity and DAR, and to improve the therapeutic index. New formats such as alternate or non-antibody protein conjugates are also making headway into the next generation ADC space. This is the moment for ADC developers.

The goal of CHI’s Fifth Annual Engineering ADCs is to bring together these cutting-edge technologies, novel concepts and creative engineering that puts ADC on the map as one of the most promising therapeutics for this decade.

KEYNOTE PRESENTATION

Fred Jacobson, Ph.D., Staff Scientist, Kadcyla™ Technical Team Leader, Genentech, Inc.


NOVEL PAYLOADS 

Fleximer Next-Generation ADCs: Creating ADCs for Low Expression Targets and Improving Therapeutic Index

Tim Lowinger, Ph.D., Senior Vice President and CSO, Mersana Therapeutics

Cancer Stem Cell Targeting with Antibody-Drug Conjugate Payloads and Linker Technologies

Riley Ennis, Ph.D., Thiel Fellow, Cell and Molecular Biology, Dartmouth College; Co-Founder, Oncolinx

Homogeneous ADCs Bearing Two Different Payloads Show Strong Synergistic Killing Effect in vivo

Sean Hu, Ph.D., Senior Vice President, Biotherapeutics Discovery, Dophen Biomed

Drug and Cytokines: Synergistic Payloads for Monoclonal Antibodies

Dario Neri, Ph.D., Professor, Department of Chemistry and Applied Biosciences, Swiss Federal institute of Technology (ETH Zurich)


LINKERS, SITES AND CONJUGATION CHEMISTRIES 

A pH-Tunable Linker: The Next Generation of Versatile Linkers for ADC

Cindy Jan Choy, Ph.D., Post-Doctoral Researcher, Chemistry, Washington State University

Enabling Splicing Inhibitors as ADC Payloads

Chakrapani Subramanyam, Ph.D., Associate Research Fellow, Worldwide Medicinal Chemistry, Pfizer R&D

Engineering of Amanitin-Based ADCs to Improve the Therapeutic Index

Andreas Pahl, Ph.D., CSO, Heidelberg Pharma

An EGFR Targeting Antibody-Drug Conjugate Engineered for Increased Tumor Specificity

Christopher Thanos, Ph.D., Director, New Molecular Entities, Halozyme Therapeutics

Site-Specific Conjugation by BTG Improves the Therapeutic Index of ADCsin vivo

Florence Lhospice, Director, Pharmaceutical Operations, R&D, Innate Pharma

Site-Specific ADC Generation Using SMARTagTM Technology

David Rabuka, Global Head, R&D, Chemical Biology, Redwood Bioscience

New Site-Specific, Traceless Antibody Conjugation Methodology

Gonçalo Bernardes, Ph.D., Group Leader, Royal Society University Research Fellow, Department of Chemistry, University of Cambridge

Engineering Site-Specific ADCs

Pam Thompson, Ph.D., Scientist I, Antibody Discovery and Protein Engineering, MedImmune


NEW FORMATS AND DESIGNS: NEXT-GENERATION ADCS, ALTERNATIVES AND NON-ANTIBODY PROTEIN CONJUGATES 

Peptide-ADCs Cross the Blood-Brain Barrier and Extend Survival in Mice with Intracranial HER2-Positive Tumors

Jean Lachowicz, Ph.D., CSO, R&D, Angiochem

Meditopes: Development of Noncovalent Peptide-Fab Interaction to Rapidly and Specifically Add Functionality to mAbs

John C. Williams, Ph.D., Associate Professor, Molecular Medicine, Beckman Research Institute at City of Hope

OptiLinked Antibody Fragments for ADCs

Ioanna Stamati, Ph.D., Team Leader, Bioconjugation, Antikor Biophama Ltd.


For more details on the conference, please contact:
Mimi Langley
Senior Conference Director
Cambridge Healthtech Institute
T: 816-472-0701
E: mlangley@healthtech.com 

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452
E: jgerardi@healthtech.com 

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781-972-5471
E: dinerstein@healthtech.com